Circumvention of multi-drug resistance of cancer cells by Chinese herbal medicines

Stella Chai¹, Kenneth KW To², Ge Lin¹*

Abstract

Multi-drug resistance (MDR) of cancer cells severely limits therapeutic outcomes. A proposed mechanism for MDR involves the efflux of anti-cancer drugs from cancer cells, primarily mediated by ATP-binding cassette (ABC) membrane transporters including P-glycoprotein. This article reviews the recent progress of using active ingredients, extracts and formulae from Chinese medicine (CM) in circumventing ABC transporters-mediated MDR. Among the ABC transporters, Pgp is the most extensively studied for its role in MDR reversal effects. While other MDR reversal mechanisms remain unclear, Pgp inhibition is a criterion for further mechanistic study. More mechanistic studies are needed to fully establish the pharmacological effects of potential MDR reversing agents.

Review

Multi-drug resistance (MDR)

Multi-drug resistance (MDR) in cancer chemotherapy refers to the ability of cancer cells to survive from treatment of a wide range of drugs [1]. In addition to the MDR induced by drugs in early exposure, the MDR cancer cells may subsequently develop cross-resistance to several unexposed and structurally unrelated chemotherapeutic agents [2]. Mechanisms of MDR include decreased uptake of drugs, alterations in cellular pathways and increased active efflux of drugs [3-5] (Figure 1). Overexpression of ATP-binding cassette (ABC) transporters is one of the most common mechanisms. ABC transporters are large membrane-bound proteins consisting of two nucleotide-binding domains (NBDs) and two transmembrane domains (TMDs) which mediate the active transport of substrate drugs out of the cell (Figure 2). Overexpression of the three major ABC transporters, i.e. P-glycoprotein (Pgp), multidrug-resistance-associated protein 1 (MRP1) and breast cancer resistance protein (BCRP/ABCG2) is frequently observed in cancer cell lines selected with chemotherapeutic drugs [6] and critical to clinical drug resistance [7].

P-glycoprotein (Pgp)

P-glycoprotein (Pgp) [8], which is also referred to as ABCB1 and MDRI, is the most studied ABC transporter. Pgp transports a wide range of chemotherapeutic agents including the anthracyclines, vincas, taxanes, etoposide and mitoxantrone [6]. Pgp is expressed in various tissues in the body. Remarkably high expression can be found in endothelial cells of capillary blood vessels in the brain as well as other organs including intestines, testes and skin [9,10]. Pgp expression is often detected in renal carcinoma, colon carcinoma, adrenal carcinoma and teratocarcinoma [9]. Substrate drugs can bind to Pgp through multiple binding sites, thereby allowing flexibility in the mechanism of transport [11,12].

Multidrug-resistance-associated protein 1 (MRP1)

The second major MDR transporter, multidrug-resistance-associated protein (MRP), was first discovered in a doxorubicin-selected lung cancer cell line [13]. A member of the ABCC subfamily, MRP1 is encoded by the ABCC1 gene [14]. Physiologically, MRP1 tends to pump drugs into the body, rather than excreting them into the bile, urine or gut [15,16]. MRP1 was highly expressed in skeletal muscles [17]. Overexpression of MRP1 is in cancer types such as lung, colon and various forms of leukaemia [18].

Breast cancer resistance protein (BCRP/ABCG2)

Recently, ABCG2 was identified in cancer cell lines selected with mitoxantrone that do not express Pgp and MRP1. As ABCG2 was simultaneously discovered by several research groups, it was also named BCRP, ABCP and MXR [19-21]. ABCG2 is expressed in a range of tissues, most abundantly in the liver and intestinal epithelia [22,23]. ABCG2 is localized in the apical region in
cells [24] and transports many cytotoxic drugs, detoxified metabolites, toxins and carcinogens [25].

**Chinese medicine and MDR**

How to tackle the MDR cells in chemotherapy is a pressing issue in cancer treatments. Verapamil was the first known Pgp inhibitor to increase the intracellular concentration of anticancer agents in MDR cells by binding to Pgp and inhibiting the Pgp-mediated efflux [26]. It was believed that anticancer drug resistance could be reversed by drug efflux inhibition. Researchers developed and tested a range of Pgp inhibitors to improve the pharmacological effects of chemotherapy in cancer patients [27-29]. However, none of these Pgp inhibitors was further developed for clinical use. Many researchers are looking into Chinese medicine (CM) for potential MDR reversing agents.

This article reviews some of the recent findings on the circumvention of ABC transporters-mediated MDR by various ingredients and extracts of CM and their formulae based on whether the MDR reversal involved Pgp alteration.

**MDR reversal involving Pgp inhibition**

*Active ingredients - alkaloids*

Tetrandrine, a calcium channel blocker, is a bisbenzylisoquinoline alkaloid isolated from the root of *Stephania tetrandra* (Fenfangji) [30]. Tetrandrine reversed MDR in vitro and modulated Pgp-mediated drug efflux [30-33]. A combination of tetrandrine with doxorubicin or vincristine in vitro demonstrated synergistic anticancer effects [34]. Tetrandrine reduced Pgp expression [35]. In mice bearing resistant MCF-1/DOX cells, tetrandrine potentiated the antitumor activities of doxorubicin without significantly increasing toxicity [36]. A synthetic halogenated form of tetrandrine increased vinblastine accumulation in a dose-dependent manner in resistant P388/DOX cell line and prolonged the life-span of tumour-bearing mice up to 25% without any side effects [37]. In a recent clinical trial, a combination of...
tetrandrine with daunorubicin, etoposide and cytarabine demonstrated antileukaemic effects in 38 patients with acute myeloid leukaemia [38].

Matrine is a quinolizidine alkaloid from *Sophora alopecuroides* (Kudouzi). In resistant K562/DOX cell line, matrine (up to 50 μg/mL, non-toxic) increased the intracellular accumulation of doxorubicin and induced its apoptotic effects [39]. Matrine enhanced the cytotoxicity of vincristine in resistant K562/VCR cell line [40]. It was proposed that matrine circumvented MDR by reducing Pgp expression [35].

Tetramethylpyrazine is an active alkaloid from *Ligusticum chuangxiong* (Chuanxiong) and a calcium channel blocker [41]. In Pgp-overexpressing resistant HL-60/VCR cell line, tetramethylpyrazine significantly reversed MDR towards various drugs such as vincristine, daunorubicin and doxorubicin [42]. Tetramethylpyrazine reduced drug efflux (up to 50%) in Pgp-overexpressing resistant K562/DOX cell line [43]. Tetramethylpyrazine decreased Pgp expression in resistant HepG2/DOX cell line [45]. However, the reduction in Pgp expression was not universally observed. For instance, Pgp level was not altered despite MDR reversal in tetramethylpyrazine-treated K562/DOX cells [46].

Peimine (also known as verticine) is a cevanine type isosteroidal alkaloid from the bulbs of *Fritillaria thunbergii* (Zhebeimu) and other *Fritillaria* species [47,48]. In resistant K562/DOX and HL-60/DOX cell lines, peimine increased intracellular concentration of daunorubicin and reversed MDR probably through inhibition of Pgp expression [49].

Berbamine is a calcium channel blocker from *Mahanoria fortunei* (Shidagonglao). In K562/DOX cell line, berbamine inhibited cell growth by inducing apoptosis in a dose-dependent manner and reduced Pgp expression thereby increasing the intracellular concentration of rhodamine-123 and doxorubicin [50,51]. In MCF-7/DOX cell line, O-(4-ethoxyl-butyl)-berbamine, a derivative of berbamine, reversed MDR by enhancing G2/M arrest and increasing the intracellular accumulation of doxorubicin [52].

**Active ingredients - saponins**

Ginsenosides are the major active components from *Panax ginseng* (Renshen). Ginsenosides are mainly triterpenoid dammarane derivatives. Several ginsenosides, namely Rg1, Rg3, Re, Rc and Rd inhibited drug efflux [53]. A combination of purified saponins containing Rb1, Rb2, Rc, Rd, Re and Rg1 reversed MDR whereas individual ginsenosides did not produce any effect [54]. Ginsenosides reversed MDR of several chemotherapeutic drugs such as homoharringtonine, cytarabine, doxorubicin and etoposide in K562/VCR and in a dose-dependent manner in K562/DOX [55]. Pgp expression decreased but bcl-2 expression remained the same [56]. Rb1 reversed MDR of harringtonolide and vincristine in K562/HHT and HL60/VCR cell lines respectively [57,58].

*Panax notoginseng* (Sanqi) total saponins reversed MDR of doxorubicin in MCF-7/DOX and K562/VCR cell lines. The mechanism may be related to the decrease of Pgp expression [59,60].

**Active ingredients - flavonoids**

Quercetin is one of the most widely distributed flavonoids in natural products including Chinese medicinal herbs such as *Sophora japonica* (Huai). Quercetin inhibited the binding of heat shock factor at the *MDR1* promoter, thereby decreasing *MDR1* transcription and reducing Pgp expression [61]. Quercetin also inhibited the overexpression of Pgp mediated by arsenite [62]. In HL-60/DOX and K562/DOX cell lines, quercetin enhanced the anticancer sensitivity to daunorubicin and doxorubicin.
decreased Pgp expression [63,64]. MDR reversal effect of quercetin was probably mediated by its action on mitochondrial membrane potential and the induction of apoptosis. Furthermore, quercetin derivatives rather than quercetin itself reversed MDR [65]. Quercetin increased the sensitivity of Pgp-overexpressing KBV1 cell line towards vinblastine and paclitaxel in a dose-dependent manner. Among many active flavonoids, quercetin was less potent than kaempferol but more effective than genistein and daidzein in reversing MDR. Genistein and daidzein had no effect on Pgp expression [66]. Although quercetin may be a potential MDR reversing agent, lethal drug-drug interaction between quercetin and digoxin has been reported. Quercetin (40 mg/kg) elevated the peak blood concentration of digoxin and caused sudden death of tested animals [67].

Curcumin, the major component in *Curcuma longa* (Jianghuang), inhibited the transport activity of all three major ABC transporters, i.e. Pgp, MRP1 and ABCG2 [68]. Curcumin reversed MDR of doxorubicin or daunorubicin in K562/DOX cell line and decreased Pgp expression in a time-dependent manner [69]. Curcumin enhanced the sensitivity to vincristine by the inhibition of Pgp in SGC7901/VCR cell line [70]. Moreover, curcumin was useful in reversing MDR associated with a decrease in bcl-2 and survivin expression but an increase in caspase-3 expression in COC1/DDP cell line [71]. The cytotoxicity of vincristine and paclitaxel were also partially restored by curcumin in resistant KBV20C cell line [72]. Curcumin derivatives reversed MDR by inhibiting Pgp efflux [72]. A chlorine substituent at the meta-or para-position on benzamide improved MDR reversal [72]. Bisdemethoxycurcumin modified from curcumin resulted in greater inhibition of Pgp expression [73]. Tetrahydrocurcumin, the major metabolite of curcumin, inhibited all three major ABC transporters [74]. Curcumin induced atypical and caspase-independent cell death in MDR cells [75]. In leukaemic cells collected from 78 childhood leukaemia patients, curcumin reduced Pgp expression [76]. A specialized nanoemulsion of curcumin is better than conventional solution form drugs in enhancing the efficiency of drug delivery into the cells, down-regulating Pgp expression, inhibiting the NFκB pathway and promoting apoptotic response [68,77].

**Active ingredients - others**

Schizandrin, the active constituents of *Schisandra chinensis* (Wuweizi), were investigated for their MDR reversal effects. Schizandrin A was the most potent in reversing MDR by enhancing apoptosis and down-regulating Pgp and total protein kinase C expression. The crude extract of *Schisandra chinensis* reversed the resistance against vincristine *in vivo* [78]. Deoxyxschizandrin and γ-schizandrin, among the nine dibenzo[a,c]cyclooctadiene lignans examined, enhanced intracellular drug concentration and induced cell cycle arrest at the G2/M phase when combined with sub-toxic dosages of doxorubicin [79]. Gomisin A, on the other hand, altered Pgp-substrate interaction by binding to Pgp simultaneously with substrates [80].

**Formulae - injections**

'Shenmai Injection', consisting of *Panax ginseng* and *Ophiopogon japonicus* (Maiddong), down-regulated Pgp expression in peripheral blood lymphocyte membrane. When used together with oxaliplatin, 5-fluorouracil or folinic acid, the injection prolonged the survival rate of colon cancer patients [81]. The injection also enhanced the efficacy of tamoxifen and nifedipine in combination therapy [82].

**Formulae - powders**

'Shenghe Powder', consisting of *Panax ginseng, Scopolularia ningpoensis* (Xuanshen) and *Atractylodes macrocephala* (Baizhu), increased the intracellular concentration of vincristine in resistant SGC-7901/VCR cell line, possibly due to the induction of apoptosis and down-regulation of Pgp and bcl-2 expression [83].

'Modified Sanwubai Powder', consisting of herbs such as *Croton tiglium* (Badou), *Platycodon grandiflorum* (Jiegeng) and *Fritillaria thunbergii*, induced apoptosis in SGC-7901 cell line and down-regulated the gene expressions of p53, bcl-2, rasP21CD44 and Pgp [84].

**Formulae - others**

Three herbal extracts used to treat diseases other than cancer, namely Ams-11, Fw-13 and Tul-17, greatly enhanced the efficacy of vincristine both *in vitro* and *in vivo* and reversed MDR in a dose-dependent manner. Tul-17 inhibited Pgp expression [85].

Oil emulsion from *Bruea javanica* (Yadanzi) reversed MDR when used together with other chemotherapeutic drugs such as vincristine, doxorubicin, cisplatin, mitomycin C, 5-fluorouracil or etoposide, probably due to down-regulation of Pgp expression or inhibition of TOPO II or both [86,87].

'Sangeng Mixture Decoction', consisting of *Reynoutria japonica* (Huzhang), *Actinidia arguta* (Mihouligen) and *Geum aleppicum* (Shuiyangmeigen), reversed MDR of doxorubicin via down-regulation of Pgp expression [88].

FFTLEG, a formula containing *Actinidia arguta*, reversed MDR in K562/DOX cell line by increasing the intracellular doxorubicin concentration [89].

R1, consisting of *Ligusticum chuanxiong*, *Curcuma longa* and *Millettia dielsiana* (Jixueteng), enhanced the anticancer activities of doxorubicin in MCF-7/DOX via down-regulation of Pgp expression [90,91].

When tested with doxorubicin, 5-fluorouracil and epirubicin in HepG2/DOX cell line, Ganai-1, a commercial product, reversed MDR via down-regulation of Pgp expression [92]. Another commercial product,
Tianfoshen, decreased Pgp expression in K562/DOX cell line and reversed MDR of doxorubicin [93]. An umbilical plaster used with 5-fluorouracil, mitomycin C or cisplatin reversed MDR via down-regulation of Pgp expression [94].

**MDR reversal not related to Pgp alteration**

**Active ingredients - alkaloids**

Dauricine is a bisbenzylisoquinoline alkaloid isolated from the root of *Menispermum dauricum* (Bianfuge) as a calcium channel blocker. Dauricine reversed vincristine resistance in MCF-7/DOX cell line [95]. However, dauricine did not alter Pgp expression in K562/DOX cell line [96]. Moreover, dauricine enhanced the cytotoxic effects of doxorubicin in HL60/HAR cell line without increasing the intracellular concentration of doxorubicin or inhibiting Pgp overexpression [97].

Daurisoline, a structural analogue of dauricine, is also a calcium channel blocker isolated from the root of *Menispermum dauricum*. Both dauricine and daurisoline sensitized MCF-7/DOX cell line towards doxorubicin and vincristine in a dose-dependent manner [98]. The MDR reversal effects of dauricine and daurisoline are comparable to those of verapamil and both alkaloids do not cause cardiovascular adverse effect [99].

**Active ingredients - saponins**

20(S)-Ginsenoside Rg3, one of the active ginsenosides from *Panax ginseng*, restored the sensitivity of resistant KBV20 cell line to various anticancer drugs, including vincristine, doxorubicin, etoposide and colchicine in a time- and dose-dependent manner. This ginsenoside competitively inhibited the binding of substrate drugs to Pgp and its binding affinity to Pgp was remarkably higher than that of verapamil. In contrast to the dose-dependent effects in vitro, 20(S)-ginsenoside Rg3 increased animal life span in an in vivo MDR model in a dose-independent manner [53].

**Active ingredients - flavonoids**

Paeonol is a weak calcium channel blocker isolated from the root of *Paeonia suffruticosa* (Mudan). In K562/DOX cell line, paeonol showed positive MDR reversal effect towards doxorubicin, daunorubicin, vincristine and vinblastine without modulating Pgp expression [100]. In parental K562 cells, paeonol induced apoptosis in a time- and dose-dependent manner [101].

**Formulae - injections**

‘KLT Injection’ consisting of the extract of *Coix lacryma-jobi* (Yiyi) enhanced the anticancer activities of paclitaxel and docetaxel and reversed MDR in a dose-dependent manner [102].

**Formulae - others**

‘Siwu Mixture’, consisting of *Paeonia lactiflora* (Shaoyao), *Rehmannia glutinosa* (Dihuang), *Angelica sinensis* (Danggui) and *Ligusticum chuanxiong*, reversed doxorubicin MDR without altering Pgp expression in K562/DOX cell line [103].

**Other mechanisms**

**Active ingredients**

Pseudolaric acid B, a major active component of *Pseudolarix kaempferi* (Jinqiansong), reversed MDR in vitro and in vivo and induced apoptosis via cell cycle arrest at G2/M phase. In either resistant cell line or nude mice model, pseudolaric acid B circumvented MDR associated with Pgp overexpression [104].

Salvinal, isolated from *Salvia miltiorrhiza* (Danshen), induced apoptosis and inhibited tubulin polymerization in various cancer cell lines, including the Pgp and MRP-overexpressing MDR cells [105].

A study on 22 compounds from CM herbs found that homoharringtonine, artemesunate and bufalin from *Cephalotaxus hainanensis* (Hainancufei), *Artemisia annua* (Qinghao) and *Bufo marinus* (Chanchu) respectively exhibited active MDR modulation [106]. Moreover, other compounds such as jatrorrhizine, indirubin, rhynchophylline [107], arsenic trioxide [108,109], psoralen [110,111], oridonin [99,112], β-elemene [113,114] also showed MDR reversal effects.

**Extracts**

Nine out of 20 extracts of *Ganoderma* species including *G. lucidum* (Lingzhi) were cytotoxic and induced apoptosis similar to etoposide and doxorubicin which are commonly used in chemotherapy. In etoposide-selected resistant cell line H69, *G. lucidum* extract increased the sensitivity to etoposide and doxorubicin significantly, possibly due to increased intracellular DNA fragmentation and caspases 3 and 9 activities [115]. Moreover, extracts of *Glycyrrhiza glabra* (Gancao), *Hedyotis diffusa* (Baihuasheshecao) and *Rheum palmatum* (Dahuang) reversed MDR by increasing the intracellular concentration of daunorubicin in SGC7901/VCR cell line [116].

**Formulae**

‘Ganli Injection’, consisting of matrine and tetramethylpyrazine hydrochloride, reversed MDR by increasing the sensitivity of 5-fluorouracil and the intracellular concentration of doxorubicin in BEL-7402/5-FU cell line [117].

‘Bushen Huayu Jiedu Formula’, consisting of *Cinnamomum cassia* (Rougui), *Psoralea corylifolia* (Buguzhi) and *Rheum palatum* (Dahuang), was tested in A549/DDP cell line and S180 tumour-bearing mice. In vitro, the formula significantly increased the intracellular concentration of cisplatin at high doses and inhibited the activity of calcium channel and LRP-56 expression at both high and low doses. In vivo, the formula improved the serum concentration, reduced the inflow and the release of Ca²⁺ and inhibited the LRP gene expression [118,119].

Four CM formulae, namely *Glycyrrhiza glabra* (GLYC), *Hedyotis diffusa* (OLEN), a formula consisting...
of 15 herbs including *Cistanche deserticola* (Roucongrong), *Rhabdosia rubescens* (Donglingcao) and *Zanthoxylum nitidum* (Liangmianzhen) (SPES), and a formula consisting of eight herbs including *Serenoa repens* (Juyezhong), *Scutellaria baicalensis* (Huangqin), *Panax ginseng* and *Glycyrrhiza glabra* (PC-SPES) were cytotoxic to cancer cell lines in a dose-dependent manner. SPES, PC-SPES, OLEN decreased the *bcl*-2 gene expression and were pro-apoptotic, while GLYC was prof necrotic without altering the over-expression of *bcl*-2 in MDR cells. Furthermore, OLEN, SPES and PC-SPES exhibited similar pharmacological effects to etoposide and vincristine [120].

Many MDR reversing alkaloids are also calcium-channel blockers probably because of (1) their structural similarity and (2) inhibition of ABC transporters by the decrease in intracellular calcium concentration. Future research is warranted for potent MDR inhibitors without other pharmacological activities.

Over-expression of ABC transporters and enhanced drug efflux are the causes for MDR. Among the ABC transporters, Pgp is the most extensively studied for its role in MDR reversal effects. While other MDR reversal mechanisms remain unclear, Pgp inhibition is a criterion for further mechanistic study. This article summarises these proposed mechanisms (Additional file 1).

**Conclusion**

As some CM active ingredients reverse MDR by directly inhibiting growth and inducing apoptosis in cancer cells, the Pgp-inhibiting CM active ingredients may also be cytotoxic to cancer cells. Future studies should explore not only the MDR reversal effects but also the cytotoxic effects of various CM active ingredients.

**Additional material**

Additional file 1: Proposed mechanisms for MDR reversal by the tested Chinese medicinal herbs. The herbs are grouped into three categories, namely active ingredients, extracts and formulae. Pgp involvement is particularly considered: (+) inhibition on Pgp; (-) no effect on Pgp.

**Abbreviations**

S-FU: S-Flurouracil; ABC: Adenosine triphosphate-binding cassette; Ara-C: cytarabine; BCRP/ABCG2: Breast cancer resistance protein; CM: Chinese medicine; DDP: Cisplatin; DNR: Daunorubicin; DOC: Docetaxel; DOX: Doxorubicin; EPI: Epirubicin; FA: Folic acid; HAR: Harringtonine; HHT: Harringtononolide; LOHP: Oxalipatin; MDR: Multi-drug resistance; MMC: Mitomycin C; MRP1/ABCC1: Multidrug-resistance-associated protein 1; NFP: Niledipine; Pgp/ABCB1: P-glycoprotein; PTX: Padratexel; TAMI: Tamoxifen; VBL: Vinblastine; VCR: Vincristine; VP-16: Etoposide

**Acknowledgements**

The work was supported by a direct grant (2008.1.079) from The Chinese University of Hong Kong.

**Author details**

1 School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China. 2 School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.

**Authors’ contributions**

SC and GL initiated the review and SC drafted the manuscript. GL and KT revised the manuscript. All authors read and approved the final version of the manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Received:** 4 March 2010  **Accepted:** 25 July 2010  **Published:** 25 July 2010

**References**

1. Mezaros A, Balogh G: Multiple Drug Resistance Lancaster, UK Gazelle Directions 2009.
2. Biedler JL, Rehm H: Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radiolautographic, and cyto genetic studies. Cancer Res 1970, 30:1174-1184.
3. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-617.
4. La Porta CAM: Drug resistance in melanoma: new perspectives. Curr Med Chem 2007, 14(4):387-91.
5. Watson JV: Introduction to Flow Cytometry Cambridge: Cambridge University Press 1991.
6. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5(3):219-34.
7. Leonard GD, Fojo T, Bates SE: The role of ABC transporters in clinical practice. Oncologist 2003, 8(5):411-424.
8. Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976, 455(1):132-162.
9. Cordoni-Cardo C, O’Brien JP, Boccia J, Casali D, Bertino JR, Melamed MR: Expression of the multidrug resistance gene product P-glycoprotein in human normal and tumor tissues. J Histochem Cytochem 1990, 38(9):1277-1287.
10. Thibault F, Tsuroo T, Hamada H, Gottesman MM, Passan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987, 84(21):7735-7739.
11. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G: Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323(5922):1718-1722.
12. Shapiro AR, Ling V: Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 1997, 250(1):130-137.
13. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeky RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Cancer Res 1993, 53(9):2687-2694.
14. Dang M, Harmon Y, Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001, 42(7):1007-1017.
15. Liu F: Mechanisms of chemotherapeutic drug resistance in cancer therapy—a quick review. Taiwan J Obstet Gynecol 2009, 48(3):239-244.
16. Roebbenf H, Yoo TA, Schippers U, Kupfers F, Koning H, Meshage H, Jansen PLM, Muller M: Increased levels of the multidrug resistance protein in lateral membranes of proliferating hepatocyte-derived cells. Gastroenterology 1997, 112(5):511-521.
17. Kruh GD, Gaughan KT, Godwin A, Chan A: Expression pattern of MRP in human tissues and adult solid tumor cell lines. J Natl Cancer Inst 1995, 87(16):1256-1258.
18. Hopfer DR, Deeky RG, Cole SP: Structural, mechanistic and clinical aspects of MRP1, Biochim Biophys Acta - Biomembranes 1999, 1461(2):359-376.
62. Kioka N, Hosokawa N, Komano T, Hayashi K, Nagata K, Ueda K. Quercetin, a bioflavonoid, inhibits the increase of human multidrug resistance gene (MDR1) expression caused by arsenite. FEMS Lett 1992, 301(3):307-309.

63. Cai X, Chen FY, Han JY, Gu CH, Zhong H, Teng Y, Ouyang RR. Reversal of multidrug resistance of HL-60 adriamycin resistant leukemia cell line by quercetin and its mechanisms. Chin J Oncol 2005, 27(6):326-329.

64. Cai X, Chen FY, Han JY, Gu CH, Zhong H, Ouyang RR. Restorative effect of quercetin on subcellular distribution of daunorubicin in multidrug resistant leukemia cell lines K562/ADM and HL-60/ADM. Chin J Cancer 2004, 23(12):1611-1615.

65. Kothari P, Khantamatt G, Phintta K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother 2005, 17(1):86-95.

66. Limtrakul P, Khantamatt G, Phintta K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother 2005, 17(1):86-95.

67. Wang Y, Chao PL, Hsiu SL, Wen K, Hou Y. Coadministration of paclitaxel and curcumin in nanoemulsion formulations To overcome multidrug resistance in tumor cells. Int J Nanomedicine 2009, 4:928-939.

68. Ganta S, Anjum M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations To overcome multidrug resistance in tumor cells. Int J Nanomedicine 2009, 4:928-939.

69. Chang HY, Pan KL, Ma FC, Jiao XY, Zhu HF, Liu JH, Huang Y, Cao YH. Study on reversing mechanism of multidrug resistance of K562/DOX cell line by curcumin and erthromycin. Chin J Hem 2006, 27(4):254-258.

70. Tang XQ, Bi H, Feng JQ, Cao JG. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmaceut Sin 2005, 26(6):109-116.

71. Lin SY, Qin ZQ, Xu YF, Wu LC, Liu LM. Study on reversing multidrug resistance of gastric carcinoma SGC-7901. Integr Cancer Ther 2007, 6(4):400-404.

72. Cao CM, Ding XD, Wang XH, Liu P. Clinical study of shenmai injection in its reversing MDR effect in late phase colon carcinoma patients. Shandong J Tradit Chin Med 2005, 24(9):529-532.

73. Limtrakul P, Khantamatt G, Phintta K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother 2005, 17(1):86-95.

74. Wang J, Yie CS, Feng ZQ. The study of effects on accumulation and efflux of intracellular adriamicyn with FTLTG for multidrug resistant cell lines K562/ADR and K562/VCR in vitro. Chin J Mod Appl Pharm 2002, 19(4):268-272.

75. Lin GF. Current situation in studying the reversing effect in multidrug-resistant in cancer cells. Taiw Pharm 2007, 16(10):63-64.

76. Chen XJ, Liu JT. Study on tumor cells’ multidrug resistance and its reversion by Chinese herbs. J Chin Integr Med 2003, 11(12):221-225.

77. Q L, Liu ZJ, Zhang J, Shi Y, Gong JP. The effects of GanA-I on the reversal of multidrug resistance in hepatocellular carcinoma. J Dig Surg 2006, 5(1):70-73.

78. Yang GW, Dong Q, Li XM. Reversal effects and mechanism study of Tianfoshen on drug resistance of human erythocyte leukemia cell strain K562/ADM. Mod J Integr Trad Chen Med 2002, 11(1):1865-1867.

79. Lu WP, Suen GZ. Effect of Zeng Xin umbilical plaster in MDR malignant ascites patient. J Chin Physician 2006, 34(2):48-50.

80. Ye ZG, Wang JH, Sun AX, Liang AH, Xue BY, Li CY, Wang L. Potentiation of vincristine-induced apoptosis by tetrandrine, neferine and dauricine in the human mammary MCF-7 multidrug-resistant cells. Yao Xue Xue Bao 2001, 36(2):96-99.

81. Li JH, Qin FQ, Yang PM. Reversal of multidrug resistance in human K562/ADM cell line by dauricine. DaLan Med Univ 2002, 24(2):94-96.

82. Liu ZM, Xu ZP, Shou LH. Progress of reversing multi-drug-resistant in TCM. Chin J Integr Trad West Med 1999, 19(12):75-79.

83. Tian F, Pan QC. Comparative study for reversing multidrug resistance in daunorubicin and daursolin. Chin J Cancer 1996, 15(6):410-414.

84. Song XR, Hou SX. Research progress in reversing multi-drug-resistant in TCM. Zhongguo Zhong Yao Za Zhi 2005, 30(16):1300-1304.

85. Sun HJ, Wang XQ, Yu LM, Zhao JY, Yang PM. The study of paeonol for reversing multi-drug resistant in human MDA-MB-231 cell line. J Pract Oncol 2006, 20(5):550-552.

86. Dong QH, Zheng S, Lu QH. Study on the effect of Kanglaite injection on MDR human leukemia cell lines. J Pract Oncol 2002, 17(1):24-26.

87. Xiao L, Shen P. Studies on the effects of Siwu Mixture on reversing multidrug resistance of human erythrocyte leukemia cell line K562/ADM. Zhongguo Zhong Yao Za Zhi 2004, 29(8):792-795.

88. Wang WK, Chu P, Chung SS, Chow LM, Zhao YZ, Yang BB, Ko BC. Pseudolaric acid B, a novel microtubule-stabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo. Clin Cancer Res 2005, 11(16):6002-6011.

89. Zhang JY, Zhang CY, Xue CC, Chen LT, Wen YS, Luo YH. Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhiza bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells. Mol Pharmacol 2004, 65(1):77-84.

90. Effert T, Davey M, Oribich A, Rucker G, Gebhart E, Davey R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1-or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis 2002, 28(3):160-168.

91. Zhang HZ, Yang L, Ren LM, Liu SM. Drug screening for reversal of multidrug resistance in tumor cell from Chinese drug active compounds in vitro. J North China Coal Med Coll 2003, 3(5):265-267.

92. Li JW. Study progress in TCM for the multidrug-resistant reversing effect. Hebei J TCM 2007, 29(6):551-560.
109. Yang SL, Pang J, Chen HP. Research progress in reversing MDR by Chinese medicine. J Hepatobiliary Surg 2008, 16(6):477-479.

110. Chang XH, Xiang Y, Huang SL. Review on revering multidrug resistance with Chinese herbs leukemia. J Bran Camp First Mil Med Univ 2004, 27(2):200-203.

111. Bao WL. Study progress in MDR reversal effect in Chinese medicine. Lishizhen Med Mater Med Res 2008, 19(12):2905-2907.

112. Suen JL, Li CJ, Liang F, Liu JX. Thoughts in using TCM to reverse multidrug resistance. Chin Arch Trad Chin Med 2006, 24(4):736-737.

113. Liu LS, Ten JH, Shi ZM. Advances in research on reversing multidrug resistance of tumour. Trad Chin Med Res 2003, 16(1):43-45.

114. Ma Q, Zhang ZS. Research review in reversing MDR by TCM. J Hunan Coll TCM 2002, 22(4):70-72.

115. Liu LS, Tien JH, Shi ZM. Advances in research on reversing multidrug resistance of tumour. Trad Chin Med Res 2003, 16(1):43-45.

116. Ma Q, Zhang ZS. Review on revering multidrug resistance with Chinese herbs leukemia. J Bran Camp First Mil Med Univ 2004, 27(2):200-203.

117. Gu YL, Chu HH, Bu P. Experimental study for reversing MDR in gastric cancer by several TCM. Trad Chin Drug Res Clin Pharmacol 2007, 18(2):114-116.

118. Gu W, Zhai XF, Zhang YN, Ling CQ. In vitro study of Ganli injection on reversing acquired multidrug resistance of human hepatocellular carcinoma. Chin Trad Herbal Drugs 2007, 38(8):871-874.

119. Cao Y, Zhang D, Zheng GJ, Yang Y, Zhang J. Study on drug resistance reversion and mechanism of bushen huayu jiedu compound recipe in lung cancer drug-resistance cells. Chin J Integr Med 2008, 14(1):46-50.

120. Sadava D, Ahn J, Zhan M, Pang ML, Ding J, Kane SE. Effects of four Chinese herbal extracts on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. Cancer Chemother Pharmacol 2002, 49(4):261-266.

doi:10.1186/1749-8546-5-26

Cite this article as: Chai et al. Circumvention of multi-drug resistance of cancer cells by Chinese herbal medicines. Chinese Medicine 2010 5:26.